# US 9,364,479 B2 · Use of a receptor-type kinase modulator for treating polycystic kidney disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,364,479 B2
- Document ID: US9364479B2
- Status: Granted
- Kind: B2
- Application number: 13/818,844
- Filed: 2011-08-25
- Published: 2013-08-22
- Granted: 2016-06-14
- Earliest claimed: 2010-08-26
- Assignees: Symphony Evolution, Inc.
- Applicants: Philip Frost; William W. N. Liao; Eric K. Rowinsky
- Inventors: Philip Frost; William W. N. Liao; Eric K. Rowinsky
- Web page: https://patentgrep.com/patent/US9364479B2

## CPC

- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61P 13/12: of the kidneys
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention comprises use of a therapeutically effective amount of the compound of the formula below for preparation of a medicament for treating polycystic kidney diseases (PKD) in a mammal, such as human or feline (e.g., Persian cat). Formula (I). Also provided are the above compound and compositions comprising it for treating PKD.

## Claims

### Claim 1

A method of treating polycystic kidney disease (PKD) in a mammal, the method comprising administering a therapeutically effective amount of a compound of formula
or a pharmaceutically acceptable salt thereof, to a mammal having PKD.

### Claim 2 (depends on 1)

The method of claim 1 wherein the mammal is a human.

### Claim 3 (depends on 1)

The method of claim 1 wherein the mammal is a feline.

### Claim 4 (depends on 3)

The method of claim 3 wherein the feline is a Persian cat.

### Claim 5 (depends on 1)

The method of claim 1 where the compound is delivered in the form of a pharmaceutical composition comprising the compound or a salt thereof and a pharmaceutically acceptable carrier, excipient, and/or diluent.

### Claim 6 (depends on 2)

The method of claim 2 where the compound is delivered in the form of a pharmaceutical composition comprising the compound or a salt thereof and a pharmaceutically acceptable carrier, excipient, and/or diluent.

### Claim 7 (depends on 3)

The method of claim 3 where the compound is delivered in the form of a pharmaceutical composition comprising the compound or a salt thereof and a pharmaceutically acceptable carrier, excipient, and/or diluent.

### Claim 8 (depends on 4)

The method of claim 4 where the compound is delivered in the form of a pharmaceutical composition comprising the compound or a salt thereof and a pharmaceutically acceptable carrier, excipient, and/or diluent.
